Edwards Lifesciences (EW) cash flow statement

Health Care Equipment · NYSE · Health Care

$105.43 -1.57% Close Nov 17, 2026 Live

TrendArc score 60 of 100 · Health 7.0 · Momentum 9.2 · Moat 5.5 · scored Nov 17, 2026 · How the score works

Free cash flow, fiscal year to December 31, 2025

$1.3 billion

up 360.5% from the year before

Edwards Lifesciences generated $1.3 billion of free cash flow in the fiscal year to December 2025: $1.6 billion of cash from operations less $260 million of capital spending. That was 22.0% of revenue, against 5.3% the year before. Over the last four quarters, to September 30, 2026, it was $1.4 billion.

What stands out

  • Over the five fiscal years to December 2025 it paid $4.3 billion in net share repurchases, 93% of its free cash flow over the same years.

Each sentence is written by a fixed rule from the figures on this page.

Free cash flow and net income, the last 10 fiscal years

$2.00B$4.00B$6.00B2016201720182019202020212022202320242025$528MFree cash flow $1.33BNet income $1.07B$2.00B$4.00B$6.00B20172019202120232025Free cash flow $1.33BNet income $1.07B

Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.

Where the cash wentFiscal year to December 31, 2025

  1. Cash from operations 1.60
  2. Capital spending -0.26
  3. Free cash flow 1.33
  4. Businesses bought and sold, net -0.05
  5. Investments bought and sold, net -0.40
  6. Net share repurchases -0.72
  7. Debt and other -0.29
  8. Net change in cash -0.12

In billions of US dollars. Outflows are grey, not red: a buyback is not a loss. "Debt and other" closes the gap to the reported change in cash. Buying marketable securities moves cash into short-term investments; the balance sheet shows both.

Cash flow statement, the last 10 fiscal years

In billions of US dollars. Each column is a fiscal year, named by the month it ended; the first column adds up the last four quarters. Cash paid out is a negative number.
Fiscal year toLast 4 quarters
to Sep 2026
Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Operating activities
Net income1.074.171.401.521.500.821.050.720.580.57
Depreciation and amortisation0.180.180.170.170.160.140.110.080.080.07
Stock-based pay0.170.160.160.140.130.110.090.080.070.060.06
Working capital and other items0.18-3.98-0.82-0.60-0.040.00-0.060.060.270.01
Cash from operations1.721.600.540.901.221.731.051.180.931.000.70
Investing activities
Capital spending-0.29-0.26-0.25-0.25-0.24-0.33-0.41-0.25-0.24-0.17-0.18
Businesses bought and sold, net-0.052.76-0.14-0.11-0.01-0.01-0.140.00-0.19-0.01
Investments bought and sold, net-0.40-0.150.580.66-1.34-0.10-0.170.34-0.230.01
Other investing-0.01-0.04-0.01-0.05-0.05-0.01-0.04-0.03-0.05-0.04
Cash from investing-0.712.310.170.25-1.72-0.53-0.600.08-0.65-0.21
Financing activities
Debt issued or repaid, net0.000.000.000.000.000.00-0.01-0.440.180.22
Shares issued less bought back-0.56-0.72-0.98-0.71-1.58-0.35-0.48-0.10-0.65-0.65-0.56
Dividends paid0.000.000.000.000.000.000.000.000.000.000.00
Other financing-0.240.000.000.000.000.000.00-0.020.000.07
Cash from financing-0.96-0.98-0.71-1.58-0.36-0.49-0.12-1.10-0.47-0.27
Exchange rate effect-0.040.040.020.020.01-0.020.00-0.010.01-0.01
Net change in cash-0.121.910.38-0.09-0.330.020.47-0.10-0.110.21
Free cash flow
Free cash flow1.421.330.290.640.971.410.650.930.690.830.53
Free cash flow margin21.3%22.0%5.3%12.8%21.8%26.9%14.8%21.4%18.5%24.2%17.8%
Free cash flow per share$2.28$0.48$1.05$1.56$2.23$1.02$1.46$1.07$1.28$0.81
Free cash flow less stock-based pay1.180.130.500.851.300.550.850.620.770.47

Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.

Edwards Lifesciences against its peers

CompanyFiscal year toFree cash flowFree cash flow margin
ResMedRMD Jun 2026$1.65B29.2%
Idexx LaboratoriesIDXX Dec 2025$1.04B24.2%
DexcomDXCM Dec 2025$1.08B23.1%
Edwards LifesciencesEW Dec 2025$1.33B22.0%
Boston ScientificBSX Dec 2025$3.66B18.2%
StrykerSYK Dec 2025$4.28B17.1%
MedtronicMDT Apr 2026$5.43B14.9%
Becton DickinsonBDX Sep 2025$2.67B12.2%
GE HealthCareGEHC Dec 2025$1.50B7.3%
Peer median17.6%

Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.

Next

Follow Edwards Lifesciences with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Edwards Lifesciences from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.